These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of moderate persistent asthma: inhalation corticosteroids in combination with long acting beta 2-adrenergic agonists (bronchodilators) then with leukotriene receptor antagonists (anti-inflammatory agents); the 'step-3-dilemma'].
    Author: Diamant Z, Dekhuijzen PN.
    Journal: Ned Tijdschr Geneeskd; 2003 Aug 30; 147(35):1681-5. PubMed ID: 14513539.
    Abstract:
    Apart from avoiding airway-irritating agents, the most important issue in the treatment of asthma is the suppression of airway inflammation by pharmaceutical treatment. Inhaled corticosteroids are the cornerstone of the medical treatment of asthma. Recent guidelines recommend the lowest possible effective dose for asthma management. In treatment steps 2 and 3, additive therapy of low to moderately high doses of inhalation corticosteroids in combination with add-on therapy with long-acting beta 2-adrenergic agonists (LABA) and leukotriene receptor antagonists (LTRA) has proved to be effective. LABA are inhaled agents with potent bronchodilator properties, whereas LTRA are taken orally and possess mainly systemic anti-inflammatory properties.
    [Abstract] [Full Text] [Related] [New Search]